TransThera-B (02617.HK): Yochanra® begins nationwide sales

NewTimeSpace News: TransThera Sciences (Nanjing), Inc. (02617.HK) said in a voluntary announcement on October 22 that the first batch of its core product Yochanra® (tinengotinib tablets) was shipped through commercial channels to pharmacies across the country on September 17, 2026, officially commencing nationwide commercial supply. On the same day, the first prescription in China was issued at Peking University Cancer Hospital, marking its entry into commercial sales in the PRC.

According to the announcement, Yochanra® is a Class 1 new drug that obtained conditional marketing approval from the NMPA on August 6, 2026 for adult patients with unresectable advanced or metastatic cholangiocarcinoma harbouring FGFR2 fusion or rearrangement who have received prior systemic therapy and FGFR inhibitor treatment. It was included in the CSCO Guidelines for the Diagnosis and Treatment of Biliary Tract Cancers as a Class II recommendation Class 2A in September 2026, making it the first approved drug for this indication in China.

The announcement said that first clinical prescriptions have recently been issued in Beijing, Shanghai, Guangdong, Jiangsu and other provinces and municipalities, with distribution completed at DTP pharmacies in multiple locations. Sales will be further rolled out to retail pharmacies in 21 provinces, municipalities and autonomous regions, leveraging the distribution and logistics network of Sinopharm Holding Jiangsu Co., Ltd. Tinengotinib is a multi-target small molecule kinase inhibitor targeting FGFR, JAK, VEGFR and Aurora, and has been granted Orphan Drug Designation and Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the EMA.